Javlord
🛑 ALL INFORMATION CLICK HERE 👈🏻👈🏻👈🏻
Javlord
An official website of the European Union An official EU website How do you know?
This medicine is authorised for use in the European Union.
First published:
08/10/2009
Last updated:
29/08/2013
This EPAR was last updated on 09/02/2022
First published:
08/10/2009
Last updated:
09/02/2022
First published:
08/10/2009
Last updated:
08/10/2009
First published:
08/02/2011
Last updated:
09/02/2022
Adopted
First published:
10/12/2014
Last updated:
10/12/2014
EMA/619399/2014
First published:
10/12/2014
Last updated:
10/12/2014
Adopted
First published:
26/09/2014
Last updated:
10/12/2014
EMA/587197/2014
First published:
30/07/2014
Last updated:
30/07/2014
EMEA/H/C/000983/PSUV/0015
First published:
08/10/2009
Last updated:
08/10/2009
First published:
25/06/2009
Last updated:
25/06/2009
EMEA/CHMP/370895/2009
★
★
★
★
★
★
★
★
★
★
★
★
★
★
★
Rating
*
- Select a value - 1 2 3 4 5
For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
All official European Union website addresses are in the europa.eu domain.
This site uses cookies to offer you a better browsing experience. Find out more on how we use cookies.
This site uses cookies to offer you a better browsing experience. Find out more on how we use cookies and how you can change your settings .
This is a summary of the European public assessment report (EPAR) for Javlor. It explains how the Committee for Medicinal Products for Human Use ( CHMP ) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Javlor.
Javlor is a concentrate for solution for infusion (drip into a vein). It contains the active substance vinflunine (25 mg/l).
Javlor is used for the treatment of adults with advanced or metastatic ‘transitional-cell carcinoma of the urothelial tract’ (a cancer that affects the lining of the bladder and the rest of the urinary tract). ‘Metastatic’ means that the cancer has spread to other parts of the body. Javlor is used when previous treatment with a platinum-containing anticancer medicine has failed.
The medicine can only be obtained with a prescription.
Treatment with Javlor should be started under the supervision of a doctor qualified to use anticancer medicines and is only given in specialised hospital units. Before administering Javlor, patients should have a blood test to check their blood-cell and haemoglobin levels. This is because low levels of haemoglobin (a protein found in red blood cells that carries oxygen around the body) and blood cells (white blood cells and platelets) are a frequent side effect of the medicine.
The dose of Javlor to be given is based on the patient’s body surface area (calculated using height and weight). The recommended dose is 320 mg per m 2 . Javlor is given as a drip into a vein over a period of 20 minutes once every three weeks. The doctor may need to adjust the dose by taking into account the patient’s age, liver or kidney function and certain side effects that the patient may be experiencing. The doctor may also delay or stop doses if the patient experiences certain side effects, including low levels of platelets and neutrophils (a type of white blood cell), and certain side effects affecting the heart, liver or lungs. Measures to prevent constipation, such as laxatives, are recommended after Javlor is given in the first week.
For more information, see the summary of product characteristics (also part of the EPAR).
The active substance in Javlor, vinflunine, belongs to the group of anticancer medicines known as the vinca alkaloids. It attaches to a protein in cells called ‘tubulin’, which is important in the formation of the internal ‘skeleton’ that cells need to assemble when they divide. By attaching to tubulin in cancer cells, vinflunine stops the formation of the skeleton, preventing the division and spread of the cancer cells.
In one main study of 370 adults with advanced or metastatic transitional-cell carcinoma of the urothelial tract, patients who were given Javlor treatment were compared with patients who were not given any anticancer medicine. During the study all patients received best supportive care (any medicines or techniques to help patients, but not other anticancer medicines). All the patients had previously received treatment with a platinum-containing medicine which failed. The main measure of effectiveness was how long the patients lived. The study also looked separately at the results in eligible patients who fulfilled strict criteria such as having had a worsening of the disease after treatment with a platinum-containing medicine.
Javlor with best supportive care was more effective than best supportive care alone in prolonging the lives of patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract. Among all patients in the study, there was no clear evidence of a difference in survival between patients who received Javlor and those who did not. However, there was a difference among patients who fulfilled the strict criteria entry requirements for the study. In this group, those given Javlor lived for 6.9 months compared with 4.3 months for patients who were not given the Javlor.
The most common side effects with Javlor (seen in more than 1 patient in 10) are neutropenia, leucopenia (low white-blood-cell counts), anaemia (low red-blood-cell counts), thrombocytopenia (low platelet counts), loss of appetite, constipation, abdominal (stomach) pain, vomiting, nausea (feeling sick), stomatitis (inflammation of the lining of the mouth), diarrhoea, alopecia (hair loss), myalgia (muscle pain), asthenia (weakness) or fatigue (tiredness), injection-site reactions, fever and weight loss. For the full list of all side effects reported with Javlor, see the package leaflet .
Javlor must not be used in people who are hypersensitive (allergic) to vinflunine or other vinca alkaloids. It must not be used in patients who have or have had a severe infection within the past two weeks or in patients with a neutrophil count of less than 1,500 per mm 3 for the first administration or less than 1,000 per mm 3 for subsequent administrations, or a platelet count less than 100,000 per mm 3 . It must also not be used in breastfeeding mothers.
The CHMP decided that Javlor’s benefits are greater than its risks and recommended that Javlor be given marketing authorisation .
The European Commission granted a marketing authorisation valid throughout the European Union for Javlor on 21 September 2009.
For more information about treatment with Javlor, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Pierre Fabre Medicament Les Cauquillous 81500 - Lavaur France
02/02/2022 Javlor - EMEA/H/C/000983 - IAIN/0023/G
Product information documents contain:
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website .
Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.
Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2.
Please do not include any personal data , such as your name or contact details. If you want to ask a question or request information from EMA, please Send a question to the European Medicines Agency .
European Medicines Agency Domenico Scarlattilaan 6 1083 HS Amsterdam The Netherlands
International non-proprietary name (INN) or common name
Carcinoma, Transitional Cell
Urologic Neoplasms
Anatomical therapeutic chemical (ATC) code
Date of issue of marketing authorisation valid throughout the European Union
Shortcuts to other sites to search off DuckDuckGo Learn More
Not many results contain javlord Search only for "javlord" ?
javlord .com Rank: (Rank based on keywords, cost and organic traffic) 60,609,866 Organic Keywords: (Number of keywords in top 20 Google SERP) 2 Organic Traffic: (Number of visitors coming from top 20 search results) 0 Organic Cost: ((How much need to spend if get same number of visitors from Google Adwords) $0.00 Adwords Keywords:
javlord .com won't load? Or, having problems with javlord .com? Check the status here and report any issues!
The dose of Javlor to be given is based on the patient's body surface area (calculated using height and weight). The recommended dose is 320 mg per m 2. Javlor is given as a drip into a vein over a period of 20 minutes once every three weeks. The doctor may need to adjust the dose by taking into account the patient's age, liver or kidney ...
Help your friends and family join the Duck Side!
Stay protected and informed with our privacy newsletters.
Check out our privacy device guides.
Switch to DuckDuckGo and take back your privacy!
Try our homepage that never shows these messages:
Help your friends and family take back their privacy!
Check out our privacy device guides.
Over $3,650,000 in DuckDuckGo privacy donations.
Shortcuts to other sites to search off DuckDuckGo Learn More
Not many results contain javlord Search only for "javlord" ?
javlord .com Rank: (Rank based on keywords, cost and organic traffic) 60,609,866 Organic Keywords: (Number of keywords in top 20 Google SERP) 2 Organic Traffic: (Number of visitors coming from top 20 search results) 0 Organic Cost: ((How much need to spend if get same number of visitors from Google Adwords) $0.00 Adwords Keywords:
javlord .com won't load? Or, having problems with javlord .com? Check the status here and report any issues!
The dose of Javlor to be given is based on the patient's body surface area (calculated using height and weight). The recommended dose is 320 mg per m 2. Javlor is given as a drip into a vein over a period of 20 minutes once every three weeks. The doctor may need to adjust the dose by taking into account the patient's age, liver or kidney ...
Help your friends and family join the Duck Side!
Stay protected and informed with our privacy newsletters.
Check out our privacy device guides.
Switch to DuckDuckGo and take back your privacy!
Try our homepage that never shows these messages:
Help your friends and family take back their privacy!
Check out our privacy device guides.
Over $3,650,000 in DuckDuckGo privacy donations.
Shortcuts to other sites to search off DuckDuckGo Learn More
Not many results contain javlord Search only for "javlord" ?
javlord .com Rank: (Rank based on keywords, cost and organic traffic) 60,609,866 Organic Keywords: (Number of keywords in top 20 Google SERP) 2 Organic Traffic: (Number of visitors coming from top 20 search results) 0 Organic Cost: ((How much need to spend if get same number of visitors from Google Adwords) $0.00 Adwords Keywords:
javlord .com won't load? Or, having problems with javlord .com? Check the status here and report any issues!
The dose of Javlor to be given is based on the patient's body surface area (calculated using height and weight). The recommended dose is 320 mg per m 2. Javlor is given as a drip into a vein over a period of 20 minutes once every three weeks. The doctor may need to adjust the dose by taking into account the patient's age, liver or kidney ...
Help your friends and family join the Duck Side!
Stay protected and informed with our privacy newsletters.
Check out our privacy device guides.
Switch to DuckDuckGo and take back your privacy!
Try our homepage that never shows these messages:
Help your friends and family take back their privacy!
Check out our privacy device guides.
Over $3,650,000 in DuckDuckGo privacy donations.
Japanese Girl Bath
Japan Massage Hidden Cam
Swapping Xxx